Post-exposure prophylaxis following non-occupational exposure to HIV: Risks, uncertainties, and ethics

International Journal of STD and AIDS

Volumn 11, Issue 7, 2000, Pages 424-427

  Mackie, Nicola E ^a   Coker, R J ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

HIV; Non occupational exposure; Post exposure prophylaxis

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; PROTEINASE INHIBITOR; ZIDOVUDINE;

DRUG COST; DRUG SAFETY; EXPOSURE; FATIGUE; GASTROINTESTINAL DISEASE; HEADACHE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MEDICAL ETHICS; PRIORITY JOURNAL; RISK MANAGEMENT; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE; SHORT SURVEY; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; ENVIRONMENTAL EXPOSURE; ETHICS, MEDICAL; HIV INFECTIONS; HUMANS; RISK FACTORS;

EID: 0034086783     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462001916182     Document Type: Short Survey

References (30)

1. 1 CDC. Provisional public health service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR 1996;45:468-72
2. 2 Department of Health. Guidelines on Post-Exposure Prophylaxis for Health Care Workers Occupationally Exposed to HIV. London: DoH, June 1997
3. 3 Geberding JL. Prophylaxis for occupational exposure to HIV. Ann Intern Med 1996;125:497-501
4. 4 Carpenter CCJ, Fischl MA, Hammer S, et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. JAMA 1996;276:146-54
5. 5 Desmond N, Coker RJ. Should preventative antiretroviral treatment be offered following sexual exposure to HIV? The case for ... Sex Transm Inf 1998;74:144-5
6. 6 Katz MH, Geberding JL. Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use. N Engl J Med 1997;336:1097-9
7. 7 Correll P, Smith D, Kippax S, et al. Experience with non-occupational HIV post-exposure prophylaxis (PEP) in New South Wales (NSW), Australia (Abstract 875). 7th European Conference on Clinical Aspects and Treatment of HIV Infection, October 1999. Lisbon, Portugal
8. 8 CDC. Management of possible sexual, injecting-drug-use, or other non-occupational exposure to HIV, including considerations related to antiretroviral therapy public health service statement. MMWR 1998;47:1-14
9. 9 Evans B, Darbyshire J, Cartledge J. Should preventative antiretroviral treatment be offered following sexual exposure to HIV? Not yet! Sex Transm Inf 1998;74:146-8
10. 10 Geberding JL. Management of occupational exposures to blood-borne viruses. N Engl J Med 1995;332:444-50
11. 11 Paul S, Jorden V, Costa SJ, et al. Recommendations for occupational exposures to HIV. N J Med Jan 1999:41-6
12. 12 Gilson L, Mkanje R, Grosskurth H, et al. Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania. Lancet 1997;350:1805-9
13. 13 Berrey MM, Shea T. Oral sex and HIV transmission (Letter). J Acquir Immune Defic Syndr Hum Retrovirol 1997;102:21-4
14. 14 Dillon B, Hecht FM, Swanson M, et al. Primary HIV infections associated with oral transmission. 7th Conference on Retroviruses and Opportunistic Infections, February 2000, San Francisco
15. 15 Black R. Animal studies of prophylaxis. Am J Med 1997;102:39-44
16. 16 Saag MS. Candidate antiretroviral agents for use in postexposure prophylaxis. Am J Med 1997;102:25-31
17. 17 Centers for Disease Control (CDC). Case-control study of HIV seroconversion in healthcare workers after percutaneous exposure to HIV-infected blood - France, United Kingdom and United States, January 1988-August 1994. MMWR 1995;44:929-33
18. 18 Connor EM, Sperling RS, Gelbert R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment: Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:1173-80
19. 19 Balsley J. Efficacy of zidovudine in preventing HIV transmission from mother to infant. Am J Med 1997;102:45-6
20. 20 Blauvelt A. A role of skin dendritic cells in the initiation of human immunodeficiency virus infection. Am J Med 1997;102:16-20
21. 21 Stigler SM. The History of Statistics: the Measurement of Uncertainty before 1900. Cambridge, MA: The Belknap Press of Harvard University Press, 1986
22. 22 Pinkerton SD, Holtgrave DR, Pinkerton HJ. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV. Arch Intern Med 1997;157:1972-80
23. 23 Pinkerton SD, Holtgrave DR, Bloom FR. Cost-effectiveness of post-exposure prophylaxis following sexual exposure to HIV. AIDS 1998;12:1067-78
24. 24 Katz M, Geberding J. Post-exposure prophylaxis after sexual exposure to HIV. J HIV Therapy 2000;5:5-9
25. 25 Murphy S, Kitchen V, Harris JRW, et al. Rape and subsequent seroconversion to HIV. BMJ 1989;299:718
26. 26 Crowe G, Forster GE, Dinsmore WW, Maw RO. A case of acute hepatitis B occurring 4 months after multiple rape. Int J STD AIDS 1996;7:133-4
27. 27 Bamberger JD, Waldo CR, Geberding JL, et al. PEP for HIV infection following sexual assault. Am J Med 1999;106:323-6
28. 28 Katz MH, Geberding JL. The care of persons with recent sexual exposure to HIV. Ann Intern Med 1998;128:306-11
29. 29 Tokars JI, Marcus R, Culver DH, et al. For the CDC Cooperative Needlestick Surveillance Group. Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. Ann Intern Med 1993;118:913-19
30. 30 Kinloch-de Loes S, Hirschel BJ, Hoen B, et al. A controlled trial of zidovudine in primary HIV infection. N Engl J Med 1995;333:408